General
[Article] Seo-jin Park, Jeong-hyeon Lim, Jiyu Lee, Jeongmin Lee, Sangsoo Hwang, Hyunjin Kim, Seunghyun Jo, Duckhyang Shin, Sang Ho MA, Myung L. Kim & Young G. Shin “Investigation of pharmacokinetic properties of a PEGylated bilirubin nanoparticle in male Sprague-Dawley rats using liquid chromatography-quadrupole time-of-flight mass spectrometry”. Xenobiotica, Issue 6649 16 Nov 2023
[Article] MITCH LESLIE. “Can ‘toxic’ bilirubin treat a variety of illnesses?”. Science, Vol 380, Issue 6649 Jun 8, 2023
Gastrointestinal
Inflammatory bowel disease
[Article] Rahman AT, Shin J, Whang CH, Jung W, Yoo D, Seo C, Cho BK, Jon S. “Bilirubin Nanomedicine Rescues Intestinal Barrier Destruction and Restores Mucosal Immunity in Colitis”. ACS Nano. 2023;17:10996–11013. (IF: 15.9)
[Article] Vítek L, Tiribelli C. “Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation”. New Engl J Med. 2020;383:684–686. (IF: 176.082)
[Article] Lee Y, Sugihara K, Gillilland MG, Jon S, Kamada N, Moon JJ. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis”. Nat Mater. 2020;19:118–126. (IF: 41.92)
[Article] Lee Y, Kim H, Kang S, Lee J, Park J, Jon S. “Bilirubin Nanoparticles as a Nanomedicine for Anti-inflammation Therapy”. Angewandte Chemie Int Ed. 2016;55:7460–7463. (IF: 16.823)
Liver
Hepatic Steatosis
[Article] Hinds TD, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. “Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate”. Front Pharmacol. 2020;11:594574. (IF: 5.988)
Cardiovascular
Myocardial infarction
[Article] Kim SJ, Park Y, Cho Y, Hwang H, Joo DJ, Huh KH, Lee J. “Proteomics Profiling of Bilirubin Nanoparticle Treatment against Myocardial Ischemia-Reperfusion Injury”. J Proteome Res. 2024;23(9):3858-3866. (IF: 3.8)
[Article] Ai W, Bae S, Ke Q, Su S, Li R, Chen Y, Yoo D, Lee E, Jon S, Kang PM. “Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice”. J Am Heart Assoc. 2021;10:e021212. (IF: 5.501)
Respiratory
Asthma
[Article] Kim DE, Lee Y, Kim M, Lee S, Jon S, Lee S-H. “Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma”. Biomaterials. 2017;140:37–44. (IF: 12.9)
Pulmonary Fibrosis
[Article] Keum H, Kim D, Kim J, Kim TW, Whang C-H, Jung W, Jon S. “A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis”. Biomaterials. 2021;275:120986–120986. (IF: 12.9)
Ischemic Reperfusion injury
Renal IRI
[Article] Yan JJ, Kim H, Kim B, Piao H, Jang JY, Kang TK, Lee WB, Kim D, Jo S, Shin D, Abuzar SM, Kim ML, Yang J, Jon S. “Synthetic Bilirubin-Based Nanomedicine Protects Against Renal Ischemia/Reperfusion Injury Through Antioxidant and Immune-Modulating Activity”. Adv. Healthcare Mater. 2025, 2403846. (IF: 10)
Hepatic IRI
[Article] Kim JY, Lee DY, Kang S, Miao W, Kim H, Lee Y, Jon S. “Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury”. Biomaterials. 2017;133:1–10. (IF: 12.9)
Transplantation
Islet Transplantation
[Article] Kim MJ, Lee Y, Jon S, Lee DY. “PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation”. Biomaterials. 2017;133:242–252. (IF: 12.9)
Kidney Transplantation
[Article] Yan JJ, Piao H, Jang JY, Kim B, Lee H, Seong M, Han KH, Choi M, Jo S, Koh HB, Kim BS, Chang YS, Jon S, Kim ML, Yang J. “Renoprotective effects of synthetic bilirubin nanomedicine against ischemia-reperfusion injury after kidney transplantation”. Clin Sci (Lond). 2026;140:845–857. (IF: 6.4)
[Article] Lee J, Kim EJ, Lee JG, Kim BS, Huh KH, Kim MS, Kim SI, Kim YS, Joo DJ. “Clinical impact of serum bilirubin levels on kidney transplant outcomes”. Sci Rep-uk. 2021;11:6889. (IF: 4.379)
GvHD
[Article] Pareek S, Flegle AS, Boagni D, Kim JY, Yoo D, Trujillo-Ocampo A, Lee S-E, Zhang M, Jon S, Im JS, “Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host Disease via a Reduction of Systemic and Local Inflammation”. Front Immunol. 2022;13:893659. (IF: 9.8)
[Article] PAreek S, Zhang M, Trujillo-Ocampo A, Kim J, Jon S, Im JS. “Bilirubin Nanoparticle as an anti-inflammatory therapy for graft versus host disease”. J Immunol. 2018;200 (1 Supplement) 55:22. (IF: 5.426)
Neuropathy
Multiple sclerosis
[Article] Kim TW, Kim Y, Jung W, Kim DE, Keum H, Son Y, Jon S. “Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells”. J Control Release. 2021;331:74–84. (IF: 11.467)
Skin
Atopic dermatitis
[Article] Kim D, Keum H, Kim R, Choi J, Prayogo MC, Kim H, Shin D, Abuzar SM, Jo S, Kim P, Park CO, Jon S. “Synthetic Bilirubin-Based Nanomedicine Alleviates Atopic Dermatitis by Reducing Oxidative Stress and Modulating Immune Responses”. Adv. Therap. 2025, 2400403. (IF: 3.7)
Psoriasis
[Article] Keum H, Kim TW, Kim Y, Seo C, Son Y, Kim J, Kim D, Jung W, Whang C-H, Jon S. “Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling”. J Control Release. 2020;325:359–369. (IF: 11.467)
Rosacea
[Article] Choi CW, Keum H, Yang S, Kang BM, Kim D, Piao H, Kim JW, Kim BR, Youn, SW, Jon S. “Bilirubin Nanomedicine Alleviates Inflammation and Angiogenesis in a Rosacea Mouse Model”. Adv Ther. 2023;2200223. (IF: 3.7)
Drug Delivery System
Cancer drug
[Article] Lee S, Lee Y, Kim H, Lee DY, Jon S. “Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy”. Biomacromolecules. 2018;19:2270–2277. (IF: 6.6)
[Article] Lee Y, Lee S, Jon S. “Biotinylated Bilirubin Nanoparticles as a Tumor Microenvironment-Responsive Drug Delivery System for Targeted Cancer Therapy”. Adv Sci. 2018;5:1800017. (IF: 14.1)
[Article] Lee DY, Kim JY, Lee Y, Lee S, Miao W, Kim HS, Min J, Jon S. “Black Pigment Gallstone Inspired Platinum-Chelated Bilirubin Nanoparticles for Combined Photoacoustic Imaging and Photothermal Therapy of Cancers”. Angewandte Chemie Int Ed. 2017;56:13684–13688. (IF: 16.823)
[Article] Lee Y, Lee S, Lee DY, Yu B, Miao W, Jon S. “Multistimuli-Responsive Bilirubin Nanoparticles for Anticancer Therapy”. Angewandte Chemie Int Ed. 2016;55:10676–10680. (IF: 16.823)
Diagnosis
Contrast agent
[Article] Jung W, Son Y, Lee DY, Jeon Y, Asaduddin M, Park SH, Jon S. “ROS-Responsive Nanobubbles for Dual-Enhanced Ultrasound and Magnetic Resonance Imaging of Tumor Oxidative Stress”. Adv Sci. 2026. (IF: 14.1)
[Article] Jung W, Asaduddin M, Keum H, Son Y, Yoo D, Kim D, Lee S, Lee DY, Roh J, Park SH, Jon S. “Longitudinal Magnetic Resonance Imaging with ROS-Responsive Bilirubin Nanoparticles Enables Monitoring of Nonalcoholic Steatohepatitis Progression to Cirrhosis”. Adv Mater. 2024;36:2305830. (IF: 26.8)
[Article] Jung W, Asaduddin M, Yoo D, Lee DY, Son Y, Kim D, Keum H, Lee J, Park SH, Jon S. “Noninvasive ROS imaging and drug delivery monitoring in the tumor microenvironment”. Biomaterials. 2024;310:122633. (IF: 12.9)
[Article] Lee DY, Kang S, Lee Y, Kim JY, Yoo D, Jung W, Lee S, Jeong YY, Lee K, Jon S. “PEGylated Bilirubin-coated Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS Detection in Whole Blood”. Theranostics. 2020;10:1997–2007. (IF: 11.6)